1. Tashkin DP. Dosing strategies for aerosol delivery to the airways. Respir Care 1991; 36: 977–88.
2. Global Initiative for Chronic Obstructive Lung Disease (GOLD) Scientific Committee. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (Updated 2006). Available at: www.goldcopd.com
3. Global Initiative for Asthma. Pocket guide for asthma management and prevention (Updated 2006). Available at: www.ginasthma.com
4. Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addiction of salmeterol in symptomatic asthma (MIASMA). Brit Med J 2000; 320: 1368–73.
5. Pauwels RA, Lofdahl CG, Postma DS et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997; 337: 1405–11.
6. O’Byrne PM, Barnes PJ, Rodriguez-Roisin R et al. Low dose inhaled budesonide and formoterol in mild persistent asthma. Am J Respir Crit Care Med 2001; 164: 1392–7.
7. Roth M, Rudiger JJ, Bihl MP et al. The β2-agonist formoterol activates the glucocorticoid receptor in vivo. Eur Respir J 2000; 18 (Suppl. 31): 437s–8s.
8. Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting β-agonists and corticosteroids. Eur Respir J 2002; 19: 182–91.
9. Bateman ED, Boushey NA, Bousquet J et al. for the GOAL Investigators Group. Can guideline defined asthma control be achieved? Am J Respir Crit Care Med 2004; 170: 836–44.
10. O'Byrne PM, Bisgaard H, Godard PP et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Resp Crit Care Med 2005; 171: 129–36.
11. Calverley PM, Boonsawat W, Cseke Z et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003; 22: 912–9.
12. Calverley PMA, Anderson JA, Celli B et al. TORCH Investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775–89.
13. Dhillon S, Keating GM. Beclometasone dipropionate/formotherol. In an HFA-propelled pressurized metered-dose inhaler. Drugs 2006; 66: 1475–83.
14. Cochrane MG, Bala MV, Downs KE et al. Inhaled corticosteroids for asthma therapy. Patient compliance, devices, and inhalation technique. Chest 2000; 117: 542–50.
15. Matthys H. CFCs and their effect on the ozone layer: the Montreal Protocol and consequences for physicians. Eur Respir Rev 1997; 7: 41, 29–31.
16. Hendeles L, Colice GL, Meyer RJ. Withdrawal of albuterol inhalers cContaining chlorofluorocarbon propellants. N Engl J Med 2007; 356: 1344–51.
17. June D. Achieving to change: challenges and successes in the formulation of CFC-free MDIs. Eur Respir Rev 1997; 7, 41: 32–4.
18. Hayman G. Why the environment matters. Br J Clin Pract Suppl 1995; 49: 2–6.
19. Tashkin DP. New devices for asthma. J Allerg Clin Immunol 1998; 101: S409–16.
20. Ganderton D. Targeted delivery of inhaled drugs: current challenges and future goal. J Aerosol Med 1999; (Suppl. 1) 12: S3–S8.
21. Brambilla G, Ganderton D, Garzia R et al. Modulation of aerosol clouds produced by pressurized inhalation aerosols. Int J Pharm 1999; 186: 53–61.
22. Woodcock A, Williams A, Batty L et al. Effects on lung function, symptoms, and bronchial hyperreactivity of low-dose inhaled beclomethasone dipropionate given with HFA-134a or CFC propellant. J Aerosol Med 2002; 15: 407–14.
23. Lewis DA, Ganderton D, Meakin BJ, Brambilla G. Modulite: a simple solution to a difficult problem. Respiration 2005; 72 (Suppl. 1): 3–5.
24. Sommerer K. Airflow resistance of different inhalation devices and visualization of the aerosol plume emitted by different metered dose inhalers. Inamed Research GmbH & Co. Hamburg, Germany 2005.
25. Acerbi D, Poli G, Haussermann S et al. Lung deposition of formoterol HFA in healthy volunteers, asthmatic and COPD patients [abstract plus poster]. Presented at the European Respiratory Society Annual Congress (ERS), Copenhagen, Denmark, September 17–21, 2005.
26. Meyer T, Brand P, Ehlich H et al. Deposition of Foradil P in human lungs: comparison of in vitro and in vivo data. J Aerosol Med 2004; 17: 43–9.
27. Acerbi D, Daley Yates PT, Poli G et al. Pharmacokinetics of a new CFC-free metered dose inhaler of beclomethasone dipropionate following multiple dosing in asthmatic patients. Resp Drug Deliv 2000; VIII 2: 395–8.
28. Anderson PB, Langley SJ, Mooney P et al. Equivalent efficacy and safety of a new HFA-134a formulation of BDP compared with the conventional CFC in adult asthmatics. J Invest Allergol Clin Immunol 2002; 12: 107–13.
29. Woodcock A, Williams A, Batty L et al. Effects on lung function, symptoms, and bronchial hyperreactivity of low-dose inhaled beclomethasone dipropionate given with HFA-134a or CFC propellant. J Aerosol Med 2002; 15: 407–14.
30. Rocca-Serra JP, Vicaut E, Lefrancois G et al. Efficacy and tolerability of a new non-extrafine formulation of beclomethasone HFA-134a in patients with asthma. Clin Drug Invest 2002; 22: 653–65.
31. Lee TL, Adler L, McLaren G et al. Assessment of efficacy and systemic safety of a new chlorofluorocarbon-free formulation of inhaled beclomethasone dipropionate in asthmatic children. Pediatr Allergy Immunol 2002; 15: 133–43.
32. Vondra V, Sladek K, Kotasova J et al. A new HFA-134a propellant in the administration of inhaled BDP via the Jet® spacer: controlled clinical trial vs. the conventional CFC. Respir Med 2002; 96: 784–9.
33. Dusser D, Vicaut E, Lefrancois G. Double-blind, double-dummy, multinational, multicenter, parallel-group design clinical trial of clinical non-inferiority of formoterol 12 mg/unit dose in a b.i.d. regimen administered via an HFA-propellant-pMDI or a dry powder inhaler in a 12-week treatment period of moderate to severe stable persistent asthma in adult patients. Respiration 2005; 72 (Suppl. 1): 20–7.
34. Bousquet J, Guenole E, Duvauchelle T et al. A randomized, double-blind, double-dummy, single-dose, crossover trial evaluating the efficacy and safety profiles of two dose levels (12 and 24 mg) of formoterol-HFA (pMDI) vs. those of a dose level (24 mg) of formoterol-DPI (ForadilR/AerolizerТМ and of placebo (pMDI or Aerolizer) in moderate to severe asthmatic patients. Respiration 2005; 72 (Suppl. 1): 13–9.
35. Houghton CM, Langley SJ, Singh SD et al. Comparison of bronchoprotective and bronchodilator effects of a single dose of formoterol delivered by hydrofluoroalkane and chlorofluorocarbon aerosols and dry powder in a double blind, placebo-controlled, crossover study. Br J Clin Pharmacol 2004; 58: 359–66.
36. Bousquet J, Huchon G, Leclerc V et al. A randomized, double-blind, double-dummy, single-dose, efficacy crossover trial comparing formoterol-HFA (pMDI) versus formoterol-DPI (Aerolizer) and placebo (pMDI or Aerolizer) in asthmatic patients. Respiration 2005; 72 (Suppl. 1): 6–12.
37. Molimard M, Guenole E, Duvauchelle T et al. A randomized, double-blind, double-dummy, safety crossover trial comparing cumulative doses up to 96μg of formoterol delivered via an HFA-134a-propelled pMDI vs. same cumulative doses of formoterol DPI and placebo in asthmatic patients. Respiration 2005; 72 (Suppl. 1): 28–34.
38. Di Marco F, Verga M, Santus P et al. Effect of formoterol, tiotropium, and their combination in patients with acute exacerbation of chronic obstructive pulmonary disease. A pilot study. Respir Med 2006; 100: 1925–32.
39. Bonnet-Gonod F, Kottakis I, Ballabio M et al. Superior efficacy of a low daily dose of a new fixed combination of beclometasone dipropionate/formoterol pMDI compared to an increased daily dose of BDP in moderate persistent asthma: a 3 month clinical study. 16th Annual Congress of the European Respiratory Society; 2006 Sep 2–6; Munich: P1237.
40. Bonnet-Gonod F, Kottakis I, Hofman T et al. Beclometasone diproprionate/formoterol in a single inhaler improves lung function and clinically meaningful outcomes in moderate to severe asthma. 16th Annual Congress of the European Respiratory Society; 2006 Sep 2–6; Munich: P1230.
41. Papi A, Paggiaro P, Nicolini G et al. Beclomethasone formoterol vs fluticasone/salmeterol inhaled combination in moderate to severe asthma. Allergy 2007; 62: 1182–8.
42. Papi A, Paggiaro PL, Nicolini G et al., on behalf of the Inhaled Combination Asthma Treatment versus SYmbicort (ICATSY) study group. Beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma. Eur Respir J 2007; 29: 682–9.
43. Lewis D, Brambilla G, Church T et al. BDP and formoterol association within a combination HFA solution MDI. Respiratory Drug delivery X 2006; 3: 939–42.
44. Barnes PJ. Beclometasone Dipropionate/Formoterol in an HFA-Propelled Pressurised Metered-Dose Inhaler. Drugs 2006; 66: 1484–5.
45. Singh D, Piccinno A, Borrill Z et al. Tolerability of high cumulative doses of the HFA modulite beclomethasone dipropionate/formoterol combination inhaler in asthmatic patients. Pulm Pharmacol Ther 2008; 21: 551–7.

С.Н.Авдеев